TELETRADER News
8/20, 5:25 PM (Source: TeleTrader)
more TeleTrader news

Pfizer, BioNTech vaccine research makes progress

Biotech companies Pfizer Inc. and BioNTech SE released on Thursday the results from their phase 1 research of coronavirus vaccine candidates, showing that they have successfully reduced the number of side effects coming from the vaccines.

In total, 332 people were included in the trials for both COVID-19 vaccines. The second vaccine, known as B2, caused fewer side effects on trial participants according to the research. Consequently, the B2 vaccine will continue to be tested in the upcoming clinical trials.

Previously, a joint coronavirus study published by the two companies showed that their vaccine generated "dose-dependent immunogenicity" among participants within weeks following a two-dose treatment.

Breaking the News / AM